SCHEMBL6098057

SCHEMBL6098057

CCOC(=O)CON1C(=O)C(=O)N(c2ccccc2SC)C1=S

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.40
ALDH1A1 P00352 6/20 0.40
HSD17B10 Q99714 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KMT2A Q03164 5/20 0.38
MEN1 O00255 3/20 0.38
KDM4E B2RXH2 1/20 0.37
MAPT P10636 2/20 0.36
GAA P10253 3/20 0.35
LMNA P02545 2/20 0.35
TSHR P16473 1/20 0.35
CA12 O43570 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HPGD P15428 1/20 0.35
PPARG P37231 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097313 0.76 KMT2A (0.45) ALDH1A1NPSR1KMT2AMEN1KDM4E
SCHEMBL5419285 0.70 ALDH1A1 (0.58) GLAALDH1A1HSD17B10NPSR1KMT2A
SCHEMBL19957705 0.66 USP2 (0.56) GLAALDH1A1NPSR1KDM4EMAPT
SCHEMBL8695358 0.62 GAA (0.45) ALDH1A1KMT2AMEN1MAPTGAA
SCHEMBL6925710 0.61 POLB (0.50) KMT2AMEN1
SCHEMBL6097865 0.61 ALDH1A1 (0.48) ALDH1A1NPSR1KMT2AMEN1KDM4E
SCHEMBL23665897 0.61 CYP4F2 (0.65) ALDH1A1HSD17B10NPSR1KDM4EMAPT
SCHEMBL11834666 0.60 TLR9 (0.61) ALDH1A1NPSR1
SCHEMBL29510534 0.60 TLR9 (0.61) ALDH1A1NPSR1
SCHEMBL2027590 0.59 TSHR (0.71) ALDH1A1HSD17B10NPSR1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135492-B2 Increases the concentration of high density lipoprotein cholesterol in the blood; dyslipoproteinemia; angina pectoris, myocardial infarction, antiarrhythmia agents, heart failure, kidney failure stroke, peripheral arterial occulsion WYETH (US) 2006-11-14 US disclosed
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis WYETH 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119889-A1 1,3-Disubstituted-2- thioxo-imidazolidine-4,5-dione derivatives useful in the treatment of atherosclerosis FFAR4, FFAR1, MSR1 GLA 4136/4885ALDH1A1 896/4885HSD17B10 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.